Discrepancies in fluoroquinolone clinical categories between the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI for Escherichia coli harbouring qnr genes and mutations in gyrA and parC

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 6, 2011, Pages 1405-1407

  Rodríguez Martínez, Jose M ^a   Briales, Alejandra ^a   Velasco, Carmen ^a   de Alba, Paula Díaz ^a   Martínez Martínez, Luis ^b,c   Pascual, Alvaro ^a,d  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^c UNIVERSITY OF CANTABRIA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

Author keywords

Enterobacteriaceae; Plasmids; Resistance

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; ESCHERICHIA COLI PROTEIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; PLASMID MEDIATED QUINOLONE RESISTANCE PROTEIN; PROTEIN PARC; PROTEIN QNR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; GENE MUTATION; GENETIC ASSOCIATION; IN VITRO STUDY; LETTER; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRACTICE GUIDELINE; PROTEIN EXPRESSION; WILD TYPE;

ANTI-BACTERIAL AGENTS; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 79956013617     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr117     Document Type: Letter

References (8)

1. Hooper DC. Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 2001; 7: 337-41.
2. Rodriguez-Martinez JM, Cano ME, Velasco C et al. Plasmid-mediated quinolone resistance: an update. J Infect Chemother 2010; doi:10.1007/s10156-010-0120-2.
3. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twentieth Informational Supplement M100-S20. CLSI, Wayne, PA, USA, 2010.
4. EUCAST Disk Diffusion Test for Routine Antimicrobial Susceptibility Testing. http://www.eucast.org/eucast_disk_diffusion_test/ (22 January 2010, date last accessed).
5. BSAC Resistance Surveillance Project. http://www.bsacsurv.org (22 January 2010, date last accessed).
6. Tamae C, Liu A, Kim K et al. Determination of antibiotic hypersensitivity among 4,000 single-gene-knockout mutants of Escherichia coli. J Bacteriol 2008; 190: 5981-8.
7. Briales A, Rodríguez-Martínez JM, Velasco C et al. In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC. Antimicrob Agents Chemother 2011; 55: 1266-9.
8. Morgan-Linnell SK, Zechiedrich L. Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli. Antimicrob Agents Chemother 2007; 51: 4205-8.